Clinical Trial Update: A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ABO2203, an mRNA-encoded CD19/CD3 T cell engager, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma; the trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• ABO2203

Snippet

Sponsor: Ruijin Hospital | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING